Your browser doesn't support javascript.
Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset.
Wynberg, Elke; van Willigen, Hugo D G; Dijkstra, Maartje; Boyd, Anders; Kootstra, Neeltje A; van den Aardweg, Joost G; van Gils, Marit J; Matser, Amy; de Wit, Marije R; Leenstra, Tjalling; de Bree, Godelieve; de Jong, Menno D; Prins, Maria.
  • Wynberg E; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
  • van Willigen HDG; Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • Dijkstra M; Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • Boyd A; Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • Kootstra NA; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
  • van den Aardweg JG; Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • van Gils MJ; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
  • Matser A; Stichting Human Immunodeficiency Virus (HIV) Monitoring, Amsterdam, The Netherlands.
  • de Wit MR; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • Leenstra T; Department of Pulmonology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • de Bree G; Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • de Jong MD; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
  • Prins M; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Clin Infect Dis ; 75(1): e482-e490, 2022 08 24.
Article in English | MEDLINE | ID: covidwho-1699566
ABSTRACT

BACKGROUND:

Few robust longitudinal data on long-term coronavirus disease 2019 (COVID-19) symptoms are available. We evaluated symptom onset, severity and recovery across the full spectrum of disease severity, up to one year after illness onset.

METHODS:

The RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged ≥18 years were enrolled following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis via the local public health service and from hospitals. Standardized symptom questionnaires were completed at enrollment, 1 week and month later, and monthly thereafter. Clinical severity was defined according to World Health Organization (WHO) criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models.

RESULTS:

Between 11 May 2020 and 1 May 2021, 342 COVID-19 patients (192 [56%] male) were enrolled, of whom 99/342 (29%) had mild, 145/342 (42%) moderate, 56/342 (16%) severe, and 42/342 (12%) critical disease. The proportion of participants who reported at least 1 persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (86.7% [95% confidence interval {CI} = 76.5-92.7%]) compared to those with mild or moderate disease (30.7% [95% CI = 21.1-40.9%] and 63.8% [95% CI = 54.8-71.5%], respectively). At 12 months after illness onset, two-fifths of participants (40.7% [95% CI = 34.2-7.1]) continued to report ≥1 symptom. Recovery was slower in female compared to male participants (adjusted hazard ratio [aHR] 0.65 [95% CI = .47-.92]) and those with a body mass index [BMI]  ≥30kg/m2 compared to BMI <25kg/m2 (hazard ratio [HR] 0.62 [95% CI = .39-.97]).

CONCLUSIONS:

COVID-19 symptoms persisted for one year after illness onset, even in some individuals with mild disease. Female sex and obesity were the most important determinants of speed of recovery from symptoms.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Female / Humans / Male Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Female / Humans / Male Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid